MA35362B1 - Nouvelle forme de cristal - Google Patents
Nouvelle forme de cristalInfo
- Publication number
- MA35362B1 MA35362B1 MA36784A MA36784A MA35362B1 MA 35362 B1 MA35362 B1 MA 35362B1 MA 36784 A MA36784 A MA 36784A MA 36784 A MA36784 A MA 36784A MA 35362 B1 MA35362 B1 MA 35362B1
- Authority
- MA
- Morocco
- Prior art keywords
- crystal form
- new crystal
- new
- compound
- relates
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Liquid Crystal Substances (AREA)
- Plural Heterocyclic Compounds (AREA)
- Glass Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
Abstract
L'invention porte sur une nouvelle forme cristallisée d'un composé.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161530104P | 2011-09-01 | 2011-09-01 | |
| PCT/EP2012/067027 WO2013030374A1 (fr) | 2011-09-01 | 2012-08-31 | Nouvelle forme de cristal |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA35362B1 true MA35362B1 (fr) | 2014-08-01 |
Family
ID=46829730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA36784A MA35362B1 (fr) | 2011-09-01 | 2014-02-28 | Nouvelle forme de cristal |
Country Status (34)
| Country | Link |
|---|---|
| US (3) | US9227953B2 (fr) |
| EP (1) | EP2751094B1 (fr) |
| JP (1) | JP6199291B2 (fr) |
| KR (2) | KR20140056297A (fr) |
| CN (1) | CN103906744A (fr) |
| AU (2) | AU2012300841C1 (fr) |
| BR (1) | BR112014004251A2 (fr) |
| CA (1) | CA2847066C (fr) |
| CL (1) | CL2014000489A1 (fr) |
| CO (1) | CO6890102A2 (fr) |
| CR (1) | CR20140098A (fr) |
| CY (1) | CY1120784T1 (fr) |
| DK (1) | DK2751094T3 (fr) |
| DO (1) | DOP2014000042A (fr) |
| EA (1) | EA027972B1 (fr) |
| ES (1) | ES2686563T3 (fr) |
| HR (1) | HRP20181375T1 (fr) |
| HU (1) | HUE041578T2 (fr) |
| IL (1) | IL230977A (fr) |
| LT (1) | LT2751094T (fr) |
| MA (1) | MA35362B1 (fr) |
| MX (1) | MX349243B (fr) |
| MY (1) | MY172885A (fr) |
| PE (1) | PE20141411A1 (fr) |
| PH (1) | PH12014500382A1 (fr) |
| PL (1) | PL2751094T3 (fr) |
| PT (1) | PT2751094T (fr) |
| RS (1) | RS57644B1 (fr) |
| SG (1) | SG2014011886A (fr) |
| SI (1) | SI2751094T1 (fr) |
| SM (1) | SMT201800455T1 (fr) |
| UA (1) | UA114607C2 (fr) |
| WO (1) | WO2013030374A1 (fr) |
| ZA (1) | ZA201401176B (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12014500382A1 (en) | 2011-09-01 | 2021-07-12 | Glaxo Group Ltd | Novel crystal form |
| EP2764866A1 (fr) | 2013-02-07 | 2014-08-13 | IP Gesellschaft für Management mbH | Inhibiteurs de l'enzyme activant nedd8 |
| CN115427397B (zh) * | 2020-03-30 | 2024-01-26 | 江苏亚虹医药科技股份有限公司 | 硝羟喹啉前药的晶型、含其的药物组合物及其制备方法和应用 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4826689A (en) | 1984-05-21 | 1989-05-02 | University Of Rochester | Method for making uniformly sized particles from water-insoluble organic compounds |
| FR2634376B1 (fr) | 1988-07-21 | 1992-04-17 | Farmalyoc | Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation |
| IT1227626B (it) | 1988-11-28 | 1991-04-23 | Vectorpharma Int | Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione |
| IT1243390B (it) | 1990-11-22 | 1994-06-10 | Vectorpharma Int | Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione. |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US5552160A (en) | 1991-01-25 | 1996-09-03 | Nanosystems L.L.C. | Surface modified NSAID nanoparticles |
| AU677783B2 (en) | 1992-06-10 | 1997-05-08 | Elan Pharma International Limited | Surface modified nsaid nanoparticles |
| AU660852B2 (en) | 1992-11-25 | 1995-07-06 | Elan Pharma International Limited | Method of grinding pharmaceutical substances |
| US5298262A (en) | 1992-12-04 | 1994-03-29 | Sterling Winthrop Inc. | Use of ionic cloud point modifiers to prevent particle aggregation during sterilization |
| US5346702A (en) | 1992-12-04 | 1994-09-13 | Sterling Winthrop Inc. | Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization |
| US5302401A (en) | 1992-12-09 | 1994-04-12 | Sterling Winthrop Inc. | Method to reduce particle size growth during lyophilization |
| US5340564A (en) | 1992-12-10 | 1994-08-23 | Sterling Winthrop Inc. | Formulations comprising olin 10-G to prevent particle aggregation and increase stability |
| US5336507A (en) | 1992-12-11 | 1994-08-09 | Sterling Winthrop Inc. | Use of charged phospholipids to reduce nanoparticle aggregation |
| US5429824A (en) | 1992-12-15 | 1995-07-04 | Eastman Kodak Company | Use of tyloxapole as a nanoparticle stabilizer and dispersant |
| US5352459A (en) | 1992-12-16 | 1994-10-04 | Sterling Winthrop Inc. | Use of purified surface modifiers to prevent particle aggregation during sterilization |
| US5587143A (en) | 1994-06-28 | 1996-12-24 | Nanosystems L.L.C. | Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions |
| US5585108A (en) | 1994-12-30 | 1996-12-17 | Nanosystems L.L.C. | Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays |
| US5560932A (en) | 1995-01-10 | 1996-10-01 | Nano Systems L.L.C. | Microprecipitation of nanoparticulate pharmaceutical agents |
| US5665331A (en) | 1995-01-10 | 1997-09-09 | Nanosystems L.L.C. | Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers |
| US5662883A (en) | 1995-01-10 | 1997-09-02 | Nanosystems L.L.C. | Microprecipitation of micro-nanoparticulate pharmaceutical agents |
| US5569448A (en) | 1995-01-24 | 1996-10-29 | Nano Systems L.L.C. | Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions |
| US5571536A (en) | 1995-02-06 | 1996-11-05 | Nano Systems L.L.C. | Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids |
| US5560931A (en) | 1995-02-14 | 1996-10-01 | Nawosystems L.L.C. | Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids |
| US5503723A (en) | 1995-02-08 | 1996-04-02 | Eastman Kodak Company | Isolation of ultra small particles |
| US5534270A (en) | 1995-02-09 | 1996-07-09 | Nanosystems Llc | Method of preparing stable drug nanoparticles |
| US5622938A (en) | 1995-02-09 | 1997-04-22 | Nano Systems L.L.C. | Sugar base surfactant for nanocrystals |
| US5518738A (en) | 1995-02-09 | 1996-05-21 | Nanosystem L.L.C. | Nanoparticulate nsaid compositions |
| US5591456A (en) | 1995-02-10 | 1997-01-07 | Nanosystems L.L.C. | Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer |
| US5573783A (en) | 1995-02-13 | 1996-11-12 | Nano Systems L.L.C. | Redispersible nanoparticulate film matrices with protective overcoats |
| US5510118A (en) | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
| US5580579A (en) | 1995-02-15 | 1996-12-03 | Nano Systems L.L.C. | Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers |
| US5718919A (en) | 1995-02-24 | 1998-02-17 | Nanosystems L.L.C. | Nanoparticles containing the R(-)enantiomer of ibuprofen |
| US5747001A (en) | 1995-02-24 | 1998-05-05 | Nanosystems, L.L.C. | Aerosols containing beclomethazone nanoparticle dispersions |
| US5565188A (en) | 1995-02-24 | 1996-10-15 | Nanosystems L.L.C. | Polyalkylene block copolymers as surface modifiers for nanoparticles |
| CH690264A5 (fr) | 1995-06-30 | 2000-06-30 | Symphar Sa | Dérivés aminophosphonates substitués, leur procédé de préparation et leur utilisation pour la préparation de compositions pharmaceutiques. |
| GB9626615D0 (en) | 1996-12-20 | 1997-02-05 | Symphar Sa | Novel compounds |
| GB9626536D0 (en) | 1996-12-20 | 1997-02-05 | Symphar Sa | Novel compounds |
| GB9626616D0 (en) | 1996-12-20 | 1997-02-05 | Symphar Sa | Novel compounds |
| WO1998035666A1 (fr) | 1997-02-13 | 1998-08-20 | Nanosystems Llc | Preparation de pastilles de naproxene nanoparticulaire |
| GB0024808D0 (en) * | 2000-10-10 | 2000-11-22 | Smithkline Beecham Plc | Novel compounds |
| JP4812751B2 (ja) | 2004-04-16 | 2011-11-09 | グラクソ グループ リミテッド | Ｌｐ−ＰＬＡ２活性およびＬｐ−ＰＬＡ２活性阻害を検出する方法 |
| WO2008140450A1 (fr) * | 2007-05-11 | 2008-11-20 | Thomas Jefferson University | Méthodes de traitement et de prévention de maladies et de troubles osseux métaboliques |
| US8962633B2 (en) | 2007-05-11 | 2015-02-24 | Thomas Jefferson University | Methods of treatment and prevention of metabolic bone diseases and disorders |
| WO2008140449A1 (fr) | 2007-05-11 | 2008-11-20 | Thomas Jefferson University | Méthodes de traitement et de prévention de maladies et de troubles neurodégénératifs |
| US20080279846A1 (en) | 2007-05-11 | 2008-11-13 | Thomas Jefferson University | Methods of treatment and prevention of neurodegenerative diseases and disorders |
| CA2687079A1 (fr) * | 2007-05-11 | 2008-11-20 | The Trustees Of The University Of Pennsylvania | Procedes de traitement des ulceres de la peau |
| US8871928B2 (en) | 2010-09-20 | 2014-10-28 | Glaxo Group Limited | Tricyclic compounds, preparation methods, and their uses |
| WO2012075917A1 (fr) | 2010-12-06 | 2012-06-14 | Glaxo Group Limited | Composés |
| JP5886310B2 (ja) | 2010-12-06 | 2016-03-16 | グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ | Ｌｐ−ＰＬＡ２により媒介される疾患または状態の処置における使用のためのピリミジノン化合物 |
| EP2651403B1 (fr) | 2010-12-17 | 2020-12-02 | Glaxo Group Limited | Procédés de traitement et de prévention de maladies oculaires |
| PH12014500382A1 (en) * | 2011-09-01 | 2021-07-12 | Glaxo Group Ltd | Novel crystal form |
| EP2764866A1 (fr) | 2013-02-07 | 2014-08-13 | IP Gesellschaft für Management mbH | Inhibiteurs de l'enzyme activant nedd8 |
-
2012
- 2012-08-31 PH PH1/2014/500382A patent/PH12014500382A1/en unknown
- 2012-08-31 RS RS20181064A patent/RS57644B1/sr unknown
- 2012-08-31 JP JP2014527685A patent/JP6199291B2/ja not_active Expired - Fee Related
- 2012-08-31 BR BR112014004251A patent/BR112014004251A2/pt not_active Application Discontinuation
- 2012-08-31 SG SG2014011886A patent/SG2014011886A/en unknown
- 2012-08-31 LT LTEP12756693.3T patent/LT2751094T/lt unknown
- 2012-08-31 SM SM20180455T patent/SMT201800455T1/it unknown
- 2012-08-31 US US14/241,913 patent/US9227953B2/en not_active Expired - Fee Related
- 2012-08-31 HR HRP20181375TT patent/HRP20181375T1/hr unknown
- 2012-08-31 DK DK12756693.3T patent/DK2751094T3/en active
- 2012-08-31 PT PT12756693T patent/PT2751094T/pt unknown
- 2012-08-31 AU AU2012300841A patent/AU2012300841C1/en not_active Ceased
- 2012-08-31 UA UAA201403151A patent/UA114607C2/uk unknown
- 2012-08-31 MX MX2014002454A patent/MX349243B/es active IP Right Grant
- 2012-08-31 WO PCT/EP2012/067027 patent/WO2013030374A1/fr not_active Ceased
- 2012-08-31 KR KR1020147005011A patent/KR20140056297A/ko not_active Ceased
- 2012-08-31 PL PL12756693T patent/PL2751094T3/pl unknown
- 2012-08-31 MY MYPI2014700470A patent/MY172885A/en unknown
- 2012-08-31 EA EA201490536A patent/EA027972B1/ru not_active IP Right Cessation
- 2012-08-31 SI SI201231371T patent/SI2751094T1/sl unknown
- 2012-08-31 ES ES12756693.3T patent/ES2686563T3/es active Active
- 2012-08-31 CA CA2847066A patent/CA2847066C/fr not_active Expired - Fee Related
- 2012-08-31 EP EP12756693.3A patent/EP2751094B1/fr active Active
- 2012-08-31 KR KR1020197017797A patent/KR20190075172A/ko not_active Ceased
- 2012-08-31 PE PE2014000274A patent/PE20141411A1/es not_active Application Discontinuation
- 2012-08-31 HU HUE12756693A patent/HUE041578T2/hu unknown
- 2012-08-31 CN CN201280051671.XA patent/CN103906744A/zh active Pending
-
2014
- 2014-02-13 IL IL230977A patent/IL230977A/en active IP Right Grant
- 2014-02-17 ZA ZA2014/01176A patent/ZA201401176B/en unknown
- 2014-02-27 CL CL2014000489A patent/CL2014000489A1/es unknown
- 2014-02-27 CR CR20140098A patent/CR20140098A/es unknown
- 2014-02-28 MA MA36784A patent/MA35362B1/fr unknown
- 2014-02-28 CO CO14043369A patent/CO6890102A2/es not_active Application Discontinuation
- 2014-02-28 DO DO2014000042A patent/DOP2014000042A/es unknown
-
2015
- 2015-11-25 US US14/951,997 patent/US9682074B2/en not_active Expired - Fee Related
-
2016
- 2016-01-28 AU AU2016200492A patent/AU2016200492B2/en not_active Ceased
- 2016-09-01 US US15/254,160 patent/US9694004B2/en not_active Expired - Fee Related
-
2018
- 2018-09-04 CY CY181100922T patent/CY1120784T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6852084A2 (es) | Nuevos compuestos sustituidos con halógeno | |
| MA35245B1 (fr) | Pyridin-2-amides utiles comme agonistes de cb2 | |
| MX2014001944A (es) | Formas cristalinas de un inhibidor de la proteasa del virus de la hepatitis c. | |
| EP2894156A4 (fr) | Cristal d'un dérivé dispiropyrrolidine | |
| BR112014029957A2 (pt) | processos para produzir determinados 2-(piridina-3-il)tiazóis | |
| CR20130369A (es) | Novedosos derivados heterocíclicos | |
| UY33735A (es) | Compuestos antivirales | |
| MX2016013735A (es) | Cristales novedosos de compuesto tetraciclico. | |
| CR11161A (es) | Procesos para la produccion de pirazoles | |
| CO6821935A2 (es) | Derivados novedosos de cefalosporinas y cmposiciones farmacéuticas de estos | |
| EP2906531A4 (fr) | Composés utiles pour la synthèse de composés benzamide | |
| MA32215B1 (fr) | Cristal de compose de benzimidazole | |
| PL2739621T3 (pl) | Kryształy związku 2-acyloamino-tiazolu | |
| BR112013030973A8 (pt) | processo para a preparação de amidas de prostaglandina | |
| MX360872B (es) | Nuevas composiciones para la produccion de poliamidas coladas. | |
| EP2940001A4 (fr) | Procédé pour produire une forme purifiée d'un composé d'amine | |
| EP2690204A4 (fr) | Procédé de fabrication d'un cristal de nitrure | |
| CY1121116T1 (el) | Νεα μεθοδος για την συνθεση αγομελατινης | |
| UY34504A (es) | Prevención de los efectos adversos causados por los anticuerpos biespecíficos EpCAMxCD3 | |
| MA35362B1 (fr) | Nouvelle forme de cristal | |
| EP2708530A4 (fr) | Procédé de synthèse stéréospécifique de composés de trétinoïne | |
| SA114350792B1 (ar) | شكل متبلر جديد من ملح الـبيميرولاست | |
| MX337610B (es) | Proceso para la preparacion de (r)-2-acetamido-n-bencil-3-metoxipr opionamida e intermediarios de la misma. | |
| EP2592080A4 (fr) | Cristal d'un sel d'un composé de pyridine fusionné | |
| CU20130092A7 (es) | Nuevo procedimiento para la síntesis de la agomelatina |